HomeSeelos Therapeutics Inc.

Seelos Therapeutics Inc.

Seelos Therapeutics Announces a Strategic Device Partnership with AptarGroup, Inc.

Strategic Device Partnership Allows Seelos to Use Aptar Pharma's Bidose (BDS) Liquid System Device with the SLS-002 Program (Intranasal Racemic Ketamine). Covers the Use of the BDS Liquid System for Intranasal Delivery of SLS-002 for the Treatment of Suicidality, Major Depressive Disorder and PTSD, and Agreement Provides Other Rights to Include Additional Undisclosed Indications